Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification

SIMPLE SUMMARY: Currently, patients with high-risk neuroblastoma are uniformly treated with maximum therapy. This study investigated a high-risk subgroup characterized by the presence of the amplified MYCN oncogene in the tumor regardless of the stage. In contrast to the corresponding high-risk subg...

Descripción completa

Detalles Bibliográficos
Autores principales: Berthold, Frank, Ernst, Angela, Ackermann, Sandra, Bartenhagen, Christoph, Christiansen, Holger, Hero, Barbara, Rosswog, Carolina, von Schweinitz, Dietrich, Klingebiel, Thomas, Schmid, Irene, Simon, Thorsten, Fischer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430929/
https://www.ncbi.nlm.nih.gov/pubmed/34503173
http://dx.doi.org/10.3390/cancers13174360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430929/
https://www.ncbi.nlm.nih.gov/pubmed/34503173
http://dx.doi.org/10.3390/cancers13174360

Ejemplares similares